The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review

Multiple Sclerosis Journal

Volumn 21, Issue 3, 2015, Pages 332-341

  Marrie, Ruth Ann ^a   Reider, Nadia ^a   Stuve, Olaf ^b   Trojano, Maria ^c   Sorensen, Per Soelberg ^d   Cutter, Gary R ^e   Reingold, Stephen C ^f   Cohen, Jeffrey ^g  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Scientific and Clinical Review Associates LLC   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cataracts; comorbidity; gastrointestinal; glaucoma; incidence; lung; Multiple sclerosis; prevalence; systematic review

Indexed keywords

COMORBIDITY; EMBASE; EYE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; KIDNEY DISEASE; LUNG DISEASE; MEDLINE; META ANALYSIS (TOPIC); MUSCULOSKELETAL DISEASE; PREVALENCE; REVIEW; SCOPUS; SYSTEMATIC REVIEW; WEB OF SCIENCE; EYE DISEASES; GASTROINTESTINAL DISEASES; KIDNEY DISEASES; LUNG DISEASES; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASES; ARTHRITIS; ASTHMA; AUTOIMMUNE HEPATITIS; CATARACT; CHRONIC HEPATITIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FACTUAL DATABASE; FIBROMYALGIA; GLAUCOMA; GOUT; HIP REPLACEMENT; IRRITABLE COLON; KIDNEY FAILURE; KNEE REPLACEMENT; PRIMARY BILIARY CIRRHOSIS; QUALITY CONTROL; SEX DIFFERENCE; VIRUS HEPATITIS;

COMORBIDITY; EYE DISEASES; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; KIDNEY DISEASES; LUNG DISEASES; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASES; PREVALENCE;

EID: 84924770769     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514564488     Document Type: Review

References (63)

1. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the {beta}-interferons for MS: A comparison between the three products. Neurology. 2004 ; 62: 628-631
2. Cohen JA. Emerging therapies for relapsing multiple sclerosis. Arch Neurol. 2009 ; 66: 821-828
3. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012 ; 78: 672-680
4. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011 ; 77: 573-579
5. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 ; 380: 1819-28
6. Marrie R, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2015 ; 21 (3). 282-293
7. MarrieRReiderNCohenJ. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. 2015; 21(3): 263-281.
8. Neyeloff J, Fuchs S, Moreira L. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012 ; 5: 52
9. Cox DR. The continuity correction. Biometrika. 1970 ; 57: 217-219
10. Christiansen CF, Christensen S, Farkas DK, et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology. 2010 ; 35: 267-274
11. De Keyser J. Autoimmunity in multiple sclerosis. Neurology. 1988 ; 38: 371-374
12. Deretzi G, Kountouras J, Koutlas E, et al. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult Scler. 2010 ; 16: 1091-1101
13. Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007 ; 29: 1-9
14. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mul Scler. 2004 ; 10: 575-581
15. Fromont A, Binquet C, Rollot F, et al. Comorbidities at multiple sclerosis diagnosis. J Neurol. 2013 ; 260: 2629-2637
16. Henderson RD, Bain CJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci. 2000 ; 7: 434-437
17. Horton M, Rudick RA, Hara-Cleaver C, et al. Validation of a Self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010 ; 35: 83-90
18. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler. 2013 ; 19: 1336-1340
19. Kang J-H, Chen Y-H, Lin H-C. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010 ; 17: 1215-1219
20. Langer-Gould A, Albers K, Van Den Eeden S, et al. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010 ; 16: 855-861
21. Levinthal DJ, Rahman A, Nusrat S, et al. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013 ;: 319201
22. Lindegard B. Diseases associated with multiple sclerosis and epilepsy. Acta Neurol Scand. 1985 ; 71: 267-277
23. Marrie R, Horwitz R, Cutter G, et al. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 ; 124: 135-141
24. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler. 2008 ; 14: 1091-1098
25. Marrie RA, Yu BN, Leung S, et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology. 2013 ; 40: 85-92
26. Nielsen N, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler. 2008 ; 14: 823-829
27. Nuyen J, Schellevisa FG, Satarianob WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol. 2006 ; 59: 1274-1284
28. Ramagopalan SV, Dyment DA, Valdar W, et al. The occurrence of autoimmune disease in Canadian families with multiple sclerosis. Lancet Neurol. 2007 ; 6: 604-610
29. Rodrigo L, Hernandez-Lahoz C, Fuentes D, et al. Prevalence of celiac disease in multiple sclerosis. BMC Neurol. 2011 ; 11: 31
30. Sadovnick A, Paty D, Yannakoulias G. Concurrence of multiple sclerosis and inflammatory bowel disease. N Engl J Med. 1989 ; 321: 762-763
31. Salvatore S, Finazzi S, Ghezzi A, et al. Multiple sclerosis and celiac disease: is there an increased risk?. Mult Scler. 2004 ; 10: 711-712
32. Seyfert S, Klapps P, Meisel C, et al. Multiple sclerosis and other immunologic diseases. Acta Neurol Scand. 1990 ; 81: 37-42
33. Tremlett HL, Evans J, Wiles CM, et al. Asthma and multiple sclerosis: an inverse association in a case-control general practice population. Q J Med. 2002 ; 95: 753-756
34. Buchanan RJ, Schiffer R, Stuifbergen A, et al. Demographic and disease characteristics of people with multiple sclerosis living in urban and rural areas. Int J MS Care. 2006 ; 8: 89-98
35. Dallmeijer AJ, Beckerman H, de Groot V, et al. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med. 2009 ; 41: 322-326
36. Finlayson M, Preissner K, Cho C. Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis. Int J MS Care. 2013 ; 15: 21-26
37. Marrie RA, Yu BN, Leung S, et al. The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: a population-based study. Mult Scler Relat Disorders. 2012 ; 1: 162-167
38. Turpin KV, Carroll LJ, Cassidy JD, et al. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler. 2007 ; 13: 1038-1045
39. Bergamaschi R, Villani S, Crabbio M, et al. Inverse relationship between multiple sclerosis and allergic respiratory diseases. Neurol Sci. 2009 ; 30: 115-118
40. Fleming ST, Blake RL. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol. 1994 ; 47: 1127-1132
41. Hemminki K, Liu X, Ji J, et al. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012 ; 127: 180-185
42. Karimi P, Modarresi SZ, Sahraian MA, et al. The relation of multiple sclerosis with allergy and atopy: a case control study. Iran J Allergy Asthma Immunol. 2013 ; 12: 182-189
43. Pedotti R, Farinotti M, Falcone C, et al. Allergy and multiple sclerosis: a population-based case-control study. Mult Scler. 2009 ; 15: 899-906
44. Ponsonby A-L, Dwyer T, Van Der Mei I, et al. Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life. Clin Exp Immunol. 2006 ; 146: 463-470
45. Sahraian MA, Jafarian S, Sheikhbahaei S, et al. Respiratory tract rather than cutaneous atopic allergy inversely associate with multiple sclerosis: a case-control study. Clin Neurol Neurosurg. 2013 ; 115: 2099-2102
46. Sheu JJ, Lin HC. Association between multiple sclerosis and chronic periodontitis: a population-based pilot study. Eur J Neurol. 2013 ; 20: 1053-1059
47. Hemminki K, Liu X, Ji J, et al. Subsequent COPD and lung cancer in patients with autoimmune disease. Eur Respir J. 2011 ; 37: 463-465
48. Lawrenson R, Wyndaele JJ, Vlachonikolis I, et al. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology. 2001 ; 20: 138-143
49. Bazelier MT, Mueller-Schotte S, Leufkens HG, et al. Risk of cataract and glaucoma in patients with multiple sclerosis. Mult Scler. 2012 ; 18: 628-638
50. Ghadirian P, Dadgostar B, Azani R, et al. A case-control study of the association between sociodemographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health. 2001 ; 92: 281-285
51. Marrie RA, Horwitz RI, Cutter G, et al. Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases. Neuroepidemiology. 2011 ; 36: 85-90
52. Salter AR, Tyry T, Vollmer T, et al. "Seeing" in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Mult Scler. 2013 ; 19: 953-960
53. Marrie RA, Horwitz R, Cutter G, et al. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012 ; 125: 180-186
54. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2003-2005. Morbidity Mortality Weekly Rep. 2006 ; 55: 1089-1092
55. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007 ; 132: 913-920
56. Mertz HR. Irritable Bowel Syndrome. New England Journal of Medicine. 2003 ; 349: 2136-2146
57. Yunus M. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treatment. 2012 ;: 584573
58. Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clinic Proc. 2011 ; 86: 907-911
59. McNeil JM. Prevalence of disabilities and associated health conditions. United States, 1999. Morbidity Mortality Weekly Rep. 2001 ; 50: 120-125
60. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
61. Pawar VS, Pawar G, Miller L-A, et al. Impact of visual impairment on health-related quality of life in multiple sclerosis. Int J MS Care. 2010 ; 12: 83-91
62. Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler. 2011 ; 17: 1464-1471
63. Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004 ; 122: 487-494